A Randomized Study Comparing Levofloxacin, Omeprazole, Nitazoxanide, and Doxycycline Versus Triple Therapy for the Eradication of Helicobacter Pylori

Overview

Journal Am J Gastroenterol

Specialty Gastroenterology

Date 2011 Oct 13

PMID 21989146

Citations 37

Authors

P Patrick Basu

Krishna Rayapudi

Tommy Pacana

Niraj James Shah

Nithya Krishnaswamy

Molly Flynn

Affiliations

Soon will be listed here.

Abstract

Objectives: Resistance to standard Helicobacter pylori (HP) treatment regimens has led to unsatisfactory cure rates in HP-infected patients. This study was designed to evaluate a novel four-drug regimen (three antibiotics and a proton pump inhibitor (PPI)) for eradication of HP infection in treatment-naive patients.

Methods: Patients with a diagnosis of HP gastritis or peptic ulcer disease confirmed using endoscopy and stool antigen testing were eligible for inclusion in this study. All patients underwent a washout period of 6 weeks from any prior antibiotic or PPI usage. Patients were then randomized to either levofloxacin, omeprazole, nitazoxanide, and doxycycline (LOAD) therapy for 7 days (LOAD-7) or 10 days (LOAD-10), including levofloxacin 250 mg with breakfast, omeprazole 40 mg before breakfast, nitazoxanide (Alina) 500 mg twice daily with meals and doxycycline 100 mg at dinner, or lansoprozole, amoxicillin, and clarithromycin (LAC) therapy for 10 days, which included lansoprozole 30 mg, amoxicillin 1 g with breakfast and dinner, and clarithromycin 500 mg with breakfast and dinner. HP eradication was confirmed by stool antigen testing at least 4 weeks after cessation of therapy.

Results: Intention-to-treat analysis revealed significant differences (P<0.05) in the respective eradication rates of the LOAD therapies (88.9% (80/90) LOAD-10, 90% (81/90) LOAD-7, 89.4% (161/180) for combined LOAD) compared with those receiving LAC, 73.3% (66/90). There were no differences in adverse effects between the groups.

Conclusions: This open-label, prospective trial demonstrates that LOAD is a highly active regimen for the treatment of HP in treatment-naive patients. A large randomized controlled trial is warranted to further evaluate the efficacy of this regimen.

Citing Articles

Treatment of Infection in Patients with Penicillin Allergy.

Liu L, Nahata M Antibiotics (Basel). 2023; 12(4).

PMID: 37107099 PMC: 10135207. DOI: 10.3390/antibiotics12040737.

Repurposing Benztropine, Natamycin, and Nitazoxanide Using Drug Combination and Characterization of Gastric Cancer Cell Lines.

Ribeiro E, Araujo D, Pereira M, Lopes B, Sousa P, Sousa A Biomedicines. 2023; 11(3).

PMID: 36979779 PMC: 10044866. DOI: 10.3390/biomedicines11030799.

Molecular Mechanisms of Antibiotic Resistance and Novel Treatment Strategies for Infections.

Srisuphanunt M, Wilairatana P, Kooltheat N, Duangchan T, Katzenmeier G, Rose J Trop Med Infect Dis. 2023; 8(3).

PMID: 36977164 PMC: 10057134. DOI: 10.3390/tropicalmed8030163.

Addition of Nitazoxanide to Standard Clarithromycin Based Triple Therapy for 2 Weeks Effectively Eradicates Treatment-Naive Infection. A Single Centre prospective, open-label study.

Jha S, Kumar R, Kumar A, Purkayastha S, Keshri R, Kumar S Middle East J Dig Dis. 2023; 14(1):77-84.

PMID: 36619726 PMC: 9489334. DOI: 10.34172/mejdd.2022.259.

Management of Infection: A Comparison between Korea and the United States.

Kim S, Hwang J Gut Liver. 2022; 16(4):503-514.

PMID: 35843686 PMC: 9289837. DOI: 10.5009/gnl210224.

References

Gisbert J, Calvet X, OConnor A, Megraud F, OMorain C . Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010; 44(5):313-25. DOI: 10.1097/MCG.0b013e3181c8a1a3. View

Loo V, Sherman P, Matlow A . Helicobacter pylori infection in a pediatric population: in vitro susceptibilities to omeprazole and eight antimicrobial agents. Antimicrob Agents Chemother. 1992; 36(5):1133-5. PMC: 188850. DOI: 10.1128/AAC.36.5.1133. View

Gisbert J, Pajares J . Helicobacter pylori "rescue" therapy after failure of two eradication treatments. Helicobacter. 2005; 10(5):363-72. DOI: 10.1111/j.1523-5378.2005.00324.x. View

Laine L, Fennerty M, Osato M, Sugg J, Suchower L, Probst P . Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol. 2001; 95(12):3393-8. DOI: 10.1111/j.1572-0241.2000.03349.x. View

Vakil N, Lanza F, Schwartz H, Barth J . Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004; 20(1):99-107. DOI: 10.1111/j.1365-2036.2004.02029.x. View

Vergara M, Vallve M, Gisbert J, Calvet X . Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003; 18(6):647-54. DOI: 10.1046/j.1365-2036.2003.01746.x. View

Malfertheiner P, Megraud F, OMorain C, Bazzoli F, El-Omar E, Graham D . Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2006; 56(6):772-81. PMC: 1954853. DOI: 10.1136/gut.2006.101634. View

de Vries A, Kuipers E . Helicobacter pylori infection and nonmalignant diseases. Helicobacter. 2010; 15 Suppl 1:29-33. DOI: 10.1111/j.1523-5378.2010.00775.x. View

Meyer J, Silliman N, Wang W, Siepman N, Sugg J, Morris D . Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med. 2002; 136(1):13-24. DOI: 10.7326/0003-4819-136-1-200201010-00008. View

10.

. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. Gut. 1997; 41(1):8-13. PMC: 1027220. DOI: 10.1136/gut.41.1.8. View

11.

Gisbert J, de la Morena F, Abraira V . Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am J Gastroenterol. 2006; 101(8):1921-30. DOI: 10.1111/j.1572-0241.2006.00668.x. View

12.

Janssen M, van Oijen A, Verbeek A, Jansen J, de Boer W . A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. Aliment Pharmacol Ther. 2001; 15(5):613-24. DOI: 10.1046/j.1365-2036.2001.00974.x. View

13.

Sisson G, Goodwin A, Raudonikiene A, Hughes N, Mukhopadhyay A, Berg D . Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother. 2002; 46(7):2116-23. PMC: 127316. DOI: 10.1128/AAC.46.7.2116-2123.2002. View

14.

Wu D, Hsu P, Wu J, Opekun A, Kuo C, Wu I . Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol. 2009; 8(1):36-41.e1. PMC: 2838430. DOI: 10.1016/j.cgh.2009.09.030. View

15.

PETERSON W . The role of antisecretory drugs in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997; 11 Suppl 1:21-5. DOI: 10.1046/j.1365-2036.11.s1.4.x. View

16.

Niv Y, Hazazi R . Helicobacter pylori recurrence in developed and developing countries: meta-analysis of 13C-urea breath test follow-up after eradication. Helicobacter. 2008; 13(1):56-61. DOI: 10.1111/j.1523-5378.2008.00571.x. View

17.

Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D . Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol. 2008; 104(1):21-5. DOI: 10.1038/ajg.2008.87. View

18.

Walker R . The fluoroquinolones. Mayo Clin Proc. 2000; 74(10):1030-7. DOI: 10.4065/74.10.1030. View

19.

Taghavi S, Jafari A, Eshraghian A . Efficacy of a new therapeutic regimen versus two routinely prescribed treatments for eradication of Helicobacter pylori: a randomized, double-blind study of doxycycline, co-amoxiclav, and omeprazole in Iranian patients. Dig Dis Sci. 2008; 54(3):599-603. DOI: 10.1007/s10620-008-0374-z. View

20.

Cammarota G, Martino A, Pirozzi G, Cianci R, Branca G, Nista E . High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther. 2004; 19(7):789-95. DOI: 10.1111/j.1365-2036.2004.01910.x. View